Marco L. Lolli

2.1k total citations
67 papers, 1.2k citations indexed

About

Marco L. Lolli is a scholar working on Molecular Biology, Organic Chemistry and Infectious Diseases. According to data from OpenAlex, Marco L. Lolli has authored 67 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 21 papers in Organic Chemistry and 16 papers in Infectious Diseases. Recurrent topics in Marco L. Lolli's work include Biochemical and Molecular Research (21 papers), HIV/AIDS drug development and treatment (15 papers) and Synthesis and Biological Evaluation (10 papers). Marco L. Lolli is often cited by papers focused on Biochemical and Molecular Research (21 papers), HIV/AIDS drug development and treatment (15 papers) and Synthesis and Biological Evaluation (10 papers). Marco L. Lolli collaborates with scholars based in Italy, United States and Denmark. Marco L. Lolli's co-authors include Donatella Boschi, Agnese Chiara Pippione, Stefano Sainas, Roberta Fruttero, Alberto Gasco, Loretta Lazzarato, Marta Giorgis, Clara Cena, Barbara Rolando and Gabriella Coruzzi and has published in prestigious journals such as Chemical Communications, FEBS Letters and Journal of Medicinal Chemistry.

In The Last Decade

Marco L. Lolli

62 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marco L. Lolli Italy 22 563 386 152 143 116 67 1.2k
Donatella Boschi Italy 21 500 0.9× 466 1.2× 126 0.8× 103 0.7× 110 0.9× 70 1.2k
Emanuele Amata Italy 27 1.0k 1.9× 393 1.0× 41 0.3× 82 0.6× 187 1.6× 75 1.6k
Qi Sun China 18 612 1.1× 362 0.9× 115 0.8× 34 0.2× 70 0.6× 55 1.4k
Benito Muñoz United States 23 925 1.6× 639 1.7× 112 0.7× 53 0.4× 133 1.1× 73 1.7k
Farah Anjum Saudi Arabia 18 594 1.1× 119 0.3× 95 0.6× 78 0.5× 104 0.9× 72 1.0k
Alberto Massarotti Italy 24 862 1.5× 1.1k 2.9× 109 0.7× 73 0.5× 118 1.0× 64 2.3k
Jeff Posakony United States 16 658 1.2× 288 0.7× 45 0.3× 74 0.5× 100 0.9× 25 1.5k
Michael Brands Germany 20 1.1k 2.0× 601 1.6× 94 0.6× 201 1.4× 353 3.0× 46 2.1k
Elizabeth A. Lunney United States 25 1.0k 1.9× 583 1.5× 119 0.8× 234 1.6× 118 1.0× 59 1.8k
Dali Yin China 18 623 1.1× 521 1.3× 287 1.9× 48 0.3× 106 0.9× 96 1.3k

Countries citing papers authored by Marco L. Lolli

Since Specialization
Citations

This map shows the geographic impact of Marco L. Lolli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco L. Lolli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco L. Lolli more than expected).

Fields of papers citing papers by Marco L. Lolli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco L. Lolli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco L. Lolli. The network helps show where Marco L. Lolli may publish in the future.

Co-authorship network of co-authors of Marco L. Lolli

This figure shows the co-authorship network connecting the top 25 collaborators of Marco L. Lolli. A scholar is included among the top collaborators of Marco L. Lolli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco L. Lolli. Marco L. Lolli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gallinella, Giorgio, Cinzia Sanna, Giovanni Appendino, et al.. (2025). Arzanol Inhibits Human Dihydroorotate Dehydrogenase and Shows Antiviral Activity. Journal of Natural Products. 88(11). 2586–2595.
2.
3.
4.
Poli, Giulio, Stefano Sainas, Menico Rizzi, et al.. (2024). An alternative conformation of the N-terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent. Acta Crystallographica Section D Structural Biology. 80(6). 386–396. 1 indexed citations
5.
Sainas, Stefano, et al.. (2024). Radiosynthesis of [ 18 F]brequinar for in vivo PET imaging of hDHODH for potential studies of acute myeloid leukemia and cancers. RSC Medicinal Chemistry. 15(9). 3147–3161. 1 indexed citations
6.
Wróbel, Tomasz M., Simonetta Oliaro‐Bosso, Therina du Toit, et al.. (2023). Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis. Biomolecules. 13(9). 1349–1349. 4 indexed citations
7.
Luganini, Anna, Maurizia Mello‐Grand, Stefano Sainas, et al.. (2023). Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication. Antiviral Research. 219. 105734–105734. 6 indexed citations
8.
Kumar, Arun, et al.. (2023). Phenothiazines as anti-cancer agents: SAR overview and synthetic strategies. European Journal of Medicinal Chemistry. 254. 115337–115337. 22 indexed citations
9.
Luganini, Anna, et al.. (2022). The Novel hDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis. Viruses. 14(10). 2281–2281. 13 indexed citations
10.
Calistri, Arianna, Anna Luganini, Barbara Mognetti, et al.. (2021). The New Generation hDHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses. Microorganisms. 9(8). 1731–1731. 25 indexed citations
11.
Pippione, Agnese Chiara, Matthew Boyko, Stefano Sainas, et al.. (2021). A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats. Brain Sciences. 12(1). 35–35. 10 indexed citations
12.
Bonanni, Davide, Marco L. Lolli, & Jürgen Bajorath. (2020). Computational Method for Structure-Based Analysis of SAR Transfer. Journal of Medicinal Chemistry. 63(3). 1388–1396. 4 indexed citations
13.
Sainas, Stefano, Franco Dosio, Donatella Boschi, & Marco L. Lolli. (2018). Chapter One - Targeting Human Onchocerciasis: Recent Advances Beyond Ivermectin. 1–38. 1 indexed citations
14.
Artuso, Emma, Ivan Visentin, Beatrice Lace, et al.. (2018). Structure–activity relationships of strigolactones via a novel, quantitative in planta bioassay. Journal of Experimental Botany. 69(9). 2333–2343. 16 indexed citations
15.
Lolli, Marco L., Stefano Sainas, Agnese Chiara Pippione, et al.. (2018). Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy. Recent Patents on Anti-Cancer Drug Discovery. 13(1). 86–105. 59 indexed citations
16.
Sainas, Stefano, Agnese Chiara Pippione, Katia Martina, et al.. (2018). Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres. Journal of Heterocyclic Chemistry. 56(2). 501–519. 11 indexed citations
17.
Sainas, Stefano, Agnese Chiara Pippione, Marta Giorgis, et al.. (2017). Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds. European Journal of Medicinal Chemistry. 129. 287–302. 44 indexed citations
18.
Pippione, Agnese Chiara, Stefano Sainas, Donatella Boschi, et al.. (2017). 4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade. MedChemComm. 8(9). 1850–1855. 15 indexed citations
19.
20.
Lolli, Marco L., et al.. (1998). Synthesis of labelled [15N3]-6-bromopurine, a useful precursor of 15N-labelled O6-alkylguanines, to be used as internal standards for quantitative GC-MS analyses. Journal of Labelled Compounds and Radiopharmaceuticals. 41(3). 243–252. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donatella Boschi Breakdown of academic impact, for papers by Emanuele Amata Breakdown of academic impact, for papers by Qi Sun Breakdown of academic impact, for papers by Benito Muñoz Breakdown of academic impact, for papers by Farah Anjum Breakdown of academic impact, for papers by Alberto Massarotti Breakdown of academic impact, for papers by Jeff Posakony Breakdown of academic impact, for papers by Michael Brands Breakdown of academic impact, for papers by Elizabeth A. Lunney Breakdown of academic impact, for papers by Dali Yin
Rankless by CCL
2026